PURPOSE: A variety of cancers, including malignant gliomas, overexpress transforming growth factor-beta (TGF-beta), which helps tumors evade effective immune surveillance through a variety of mechanisms, including inhibition of CD8(+) CTLs and enhancing the generation of regulatory T (T(reg)) cells. We hypothesized that inhibition of TGF-beta would improve the efficacy of vaccines targeting glioma-associated antigen (GAA)-derived CTL epitopes by reversal of immunosuppression. EXPERIMENTAL DESIGN: Mice bearing orthotopic GL261 gliomas were treated systemically with a TGF-beta-neutralizing monoclonal antibody, 1D11, with or without s.c. vaccinations of synthetic peptides for GAA-derived CTL epitopes, GARC-1 (77-85) and EphA2 (671-679), emulsified in incomplete Freund's adjuvant. RESULTS: Mice receiving the combination regimen exhibited significantly prolonged survival compared with mice receiving either 1D11 alone, GAA vaccines alone, or mock treatments alone. TGF-beta neutralization enhanced the systemic induction of antigen-specific CTLs in glioma-bearing mice. Flow cytometric analyses of brain-infiltrating lymphocytes revealed that 1D11 treatment suppressed phosphorylation of Smad2, increased GAA-reactive/IFN-gamma-producing CD8(+) T cells, and reduced CD4(+)/FoxP3(+) T(reg) cells in the glioma microenvironment. Neutralization of TGF-beta also upregulated plasma levels of interleukin-12, macrophage inflammatory protein-1 alpha, and IFN-inducible protein-10, suggesting a systemic promotion of type-1 cytokine/chemokine production. Furthermore, 1D11 treatment upregulated plasma interleukin-15 levels and promoted the persistence of GAA-reactive CD8(+) T cells in glioma-bearing mice. CONCLUSIONS: These data suggest that systemic inhibition of TGF-beta by 1D11 can reverse the suppressive immunologic environment of orthotopic tumor-bearing mice both systemically and locally, thereby enhancing the therapeutic efficacy of GAA vaccines.
PURPOSE: A variety of cancers, including malignant gliomas, overexpress transforming growth factor-beta (TGF-beta), which helps tumors evade effective immune surveillance through a variety of mechanisms, including inhibition of CD8(+) CTLs and enhancing the generation of regulatory T (T(reg)) cells. We hypothesized that inhibition of TGF-beta would improve the efficacy of vaccines targeting glioma-associated antigen (GAA)-derived CTL epitopes by reversal of immunosuppression. EXPERIMENTAL DESIGN:Mice bearing orthotopic GL261gliomas were treated systemically with a TGF-beta-neutralizing monoclonal antibody, 1D11, with or without s.c. vaccinations of synthetic peptides for GAA-derived CTL epitopes, GARC-1 (77-85) and EphA2 (671-679), emulsified in incomplete Freund's adjuvant. RESULTS:Mice receiving the combination regimen exhibited significantly prolonged survival compared with mice receiving either 1D11 alone, GAA vaccines alone, or mock treatments alone. TGF-beta neutralization enhanced the systemic induction of antigen-specific CTLs in glioma-bearingmice. Flow cytometric analyses of brain-infiltrating lymphocytes revealed that 1D11 treatment suppressed phosphorylation of Smad2, increased GAA-reactive/IFN-gamma-producing CD8(+) T cells, and reduced CD4(+)/FoxP3(+) T(reg) cells in the glioma microenvironment. Neutralization of TGF-beta also upregulated plasma levels of interleukin-12, macrophage inflammatory protein-1 alpha, and IFN-inducible protein-10, suggesting a systemic promotion of type-1 cytokine/chemokine production. Furthermore, 1D11 treatment upregulated plasma interleukin-15 levels and promoted the persistence of GAA-reactive CD8(+) T cells in glioma-bearingmice. CONCLUSIONS: These data suggest that systemic inhibition of TGF-beta by 1D11 can reverse the suppressive immunologic environment of orthotopic tumor-bearing mice both systemically and locally, thereby enhancing the therapeutic efficacy of GAA vaccines.
Authors: Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei Journal: J Neurooncol Date: 2006-08-29 Impact factor: 4.130
Authors: James J Kobie; Rita S Wu; Robert A Kurt; Sunming Lou; Miranda K Adelman; Luke J Whitesell; Lalitha V Ramanathapuram; Carlos L Arteaga; Emmanuel T Akporiaye Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Junichi Eguchi; Manabu Hatano; Fumihiko Nishimura; Xinmei Zhu; Jill E Dusak; Hidemitsu Sato; Ian F Pollack; Walter J Storkus; Hideho Okada Journal: Cancer Res Date: 2006-06-01 Impact factor: 12.701
Authors: Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie Journal: Proc Natl Acad Sci U S A Date: 2004-12-27 Impact factor: 11.205
Authors: Masaki Terabe; Faith C Robertson; Katharine Clark; Emma De Ravin; Anja Bloom; David J Venzon; Shingo Kato; Amer Mirza; Jay A Berzofsky Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada Journal: J Clin Invest Date: 2017-03-20 Impact factor: 14.808
Authors: Bingtao Tang; Zong Sheng Guo; David L Bartlett; David Z Yan; Claire P Schane; Diana L Thomas; Jia Liu; Grant McFadden; Joanna L Shisler; Edward J Roy Journal: Clin Cancer Res Date: 2020-02-04 Impact factor: 12.531
Authors: Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa Journal: Clin Cancer Res Date: 2013-04-23 Impact factor: 12.531